Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | KMT5A | Q9NQR1 | 12/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | UBE2N | P61088 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | PGK1 | P00558 | 2/20 | 0.54 |
| ▸ | KDM1A | O60341 | 1/20 | 0.51 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.51 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.51 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3974916 | 0.90 | KDM4E (0.77) | TLR9KDM4EALDH1A1MAPTKMT5A | |
| SCHEMBL31453017 | 0.85 | TLR9 (0.72) | TLR9KDM4EALDH1A1MAPTKMT5A | |
| SCHEMBL3979247 | 0.84 | ALDH1A1 (0.54) | TLR9KDM4EALDH1A1MAPTPOLB | |
| SCHEMBL3974654 | 0.83 | ACP1 (0.54) | TLR9KDM4EALDH1A1MAPTKMT5A | |
| SCHEMBL3980578 | 0.83 | MAPK1 (0.58) | TLR9MAPTTDP1 | |
| SCHEMBL3980055 | 0.82 | PGK1 (0.62) | TLR9KDM4EALDH1A1MAPTKMT5A | |
| SCHEMBL3980630 | 0.82 | KDM4E (0.52) | TLR9KDM4EALDH1A1MAPTKMT5A | |
| SCHEMBL12175518 | 0.79 | TLR9 (1.00) | TLR9KDM4EALDH1A1MAPTKMT5A | |
| SCHEMBL29360163 | 0.79 | TLR9 (1.00) | TLR9KDM4EALDH1A1MAPTKMT5A | |
| SCHEMBL3975061 | 0.79 | TLR9 (0.52) | TLR9KDM4EALDH1A1MAPTKMT5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7547702-B2 | 4-amino-quinazolines | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2009-06-16 | — | — | US | disclosed |
| US-20060019974-A1 | Glycoprotein antagonist; anticholesterol agents; cardiovascular disorders; strokes; antiischemic agents | ORTHO-MCNEIL PHARMACEUTICALS, INC. | 2006-01-26 | — | — | US | disclosed |
| WO-2004030672-A1 | USE OF 4 AMINO-QUINAZOLINES AS ANTI CANCER AGENTS | MERCK PATENT GMBH (DE) | 2004-04-15 | — | — | WO | disclosed |
| EP-1318984-A1 | 4-AMINO-QUINAZOLINES | MERCK PATENT GmbH (DE) | 2003-06-18 | — | — | EP | disclosed |
| WO-2002024667-A1 | 4-AMINO-QUINAZOLINES | MERCK PATENT GMBH (DE) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060019974-A1 | Glycoprotein antagonist; anticholesterol agents; cardiovascular disorders; strokes; antiischemic agents | SERPINA3, APOL1, MGAT3 | TLR9 4215/4885KDM4E 4808/4885ALDH1A1 1459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.